Atara Biotherapeutics

Impact: Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. Its stock price experienced significant declines following FDA decisions.

Impact: Atara Biotherapeutics granted restricted stock units to newly hired employees as an inducement for employment, which is a common practice for attracting talent and can positively impact employee retention and motivation.

Impact: Atara Biotherapeutics, co-founded by Fred Ramsdell, is actively developing therapies based on the discoveries of regulatory T cells, with support from Regeneron, indicating potential for future market clearance.

Impact: Atara Biotherapeutics is involved in a class action lawsuit due to allegations that manufacturing issues and deficiencies in the ALLELE study made FDA approval of tabelecleucel BLA unlikely, and that its regulatory prospects were overstated.

Impact: Fred Ramsdell is a scientific adviser for Atara Biotherapeutics, which is mentioned as his affiliation.